GlassScriptPhysician profile
Pablito G Nagpala
NPI 1306820071
$10,812.06
in general payments reported to CMS, 2019-2025
40 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 75% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $960 · 2021: $1,423 · 2022: $1,703 · 2023: $1,602 · 2024: $1,675 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,888 · Education: $35.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,887.73 |
| Education | $35.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,813.56 | 2019-2025 | |
| Novo Nordisk INC | $910.20 | 2019-2025 | Wegovy, Sogroya |
| Arbor Pharmaceuticals, INC. | $859.65 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $773.86 | 2022-2025 | Skytrofa, Yorvipath |
| Dexcom, INC. | $613.34 | 2021-2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $582.53 | 2019-2024 | Omnipod |
| Tandem Diabetes Care, INC. | $555.98 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $545.67 | 2019-2025 | |
| Amphastar Pharmaceuticals, INC. | $538.40 | 2023-2025 | Baqsimi |
| Tolmar, INC. | $488.15 | 2023-2025 | Fensolvi |
| Lilly USA, LLC | $355.91 | 2019-2023 | Baqsimi, Lyumjev |
| Endo Pharmaceuticals INC. | $294.26 | 2019-2024 | Supprelin |
| Mannkind Corporation | $246.05 | 2020-2024 | Afrezza |
| Tolmar Pharmaceuticals, INC. | $220.92 | 2020-2022 | |
| Kyowa Kirin, INC. | $206.82 | 2023-2025 | Crysvita |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $183.92 | 2021-2023 | Imcivree |
| Beta Bionics, INC. | $167.62 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Azurity Pharmaceuticals, INC. | $154.42 | 2023-2025 | Triptodur, Triptodur |
| Horizon Therapeutics Plc | $127.29 | 2019-2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $123.70 | 2024-2025 | |
| Abbott Laboratories | $123.43 | 2021-2022 | |
| Vistapharm, INC. | $117.84 | 2021 | |
| Xeris Pharmaceuticals, INC. | $90.86 | 2020-2023 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $82.70 | 2021-2025 | Strensiq |
| Embecta Corp. | $75.25 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Medtronic, INC. | $70.61 | 2021-2024 | Minimed 780g |
| Neurocrine Biosciences, INC. | $58.72 | 2024-2025 | |
| Zealand Pharma US, INC. | $58.49 | 2021-2022 | |
| Amgen INC. | $49.89 | 2024 | Tepezza |
| Ibsa Pharma INC. | $46.19 | 2020-2022 | |
| Becton, Dickinson and Company | $44.71 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $43.51 | 2022-2023 | |
| Biomarin Pharmaceutical INC. | $41.82 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $23.84 | 2019 | |
| Bigfoot Biomedical INC | $22.60 | 2022 | |
| Sequel Med Tech, LLC | $22.48 | 2025 | Twiist |
| Medtronic Minimed, INC. | $21.12 | 2019 | |
| Sandoz INC. | $19.59 | 2019 | |
| Endo USA, INC. | $19.34 | 2024 | Supprelin |
| Lifescan, INC. | $16.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablito Nagpala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.